More than 60% of approved compounds and new drug applications (NDA) are natural products or related compounds, apart from biological products (vaccines or monoclonal antibodies).
The main objective of this project is to obtain and preclinically evaluate natural compounds with neuroprotective and/or hypolipemiant activity. Through its different screening platforms, Neuron BioPharma studies a large amount of natural extracts to discover their neuroprotective, hypolipemiant or anti-oxidant activity.